Concord Biotech Limited — Others, 12-11-2024: Copy of Newspaper Publication

Concord Biotech Limited has announced a board meeting on November 11, 2024, to review its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2024. The company reported total income from operations of ₹3,184.05 crore, with a net profit of ₹1,036.55 crore before tax and ₹943.08 crore after tax. Earnings per share (EPS) stood at ₹29.13 for the half-year. The positive financial performance may enhance investor confidence in the company, highlighting its robust operational strength amidst market uncertainties.